The impact of phosphate lowering agents on clinical and laboratory outcomes in chronic kidney disease patients: a systematic review and meta-analysis of …
J Phannajit, N Wonghakaeo, K Takkavatakarn… - Journal of …, 2022 - Springer
Background Besides reducing hyperphosphatemia in chronic kidney disease (CKD)
patients, phosphate lowering agents might provide beneficial effects on clinical and …
patients, phosphate lowering agents might provide beneficial effects on clinical and …
Comparative Efficacy and Acceptability of 12 Phosphorus-Lowering Drugs in Adults with Hyperphosphatemia and Chronic Kidney Disease: A Systematic Review and …
H Luo, J Feng, G Xue, Y Zhang, Y Li, X Huang… - Blood …, 2023 - karger.com
Background: Hyperphosphatemia is associated with cardiovascular morbidity and mortality
in adults with chronic kidney disease (CKD). Drug therapy has an irreplaceable role in the …
in adults with chronic kidney disease (CKD). Drug therapy has an irreplaceable role in the …
The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney …
S Habbous, S Przech, R Acedillo… - Nephrology Dialysis …, 2017 - academic.oup.com
Background. It remains unclear which phosphate binders should be preferred for
hyperphosphatemia management in chronic kidney disease (CKD). Methods. We performed …
hyperphosphatemia management in chronic kidney disease (CKD). Methods. We performed …
[HTML][HTML] Sevelamer use and mortality in people with chronic kidney disease stages 4 and 5 not on dialysis
P Molina, MD Molina, JJ Carrero, V Escudero… - Journal of Clinical …, 2023 - mdpi.com
Rationale and objective: Data suggest that non-calcium-based binders, and specifically
sevelamer, may lead to lower rates of death when compared with calcium-based binders in …
sevelamer, may lead to lower rates of death when compared with calcium-based binders in …
Clinical evaluation of the safety, efficacy and tolerability of lanthanum carbonate in the management of hyperphosphatemia in patients with end-stage renal disease
V Cernaro, S Calimeri, A Laudani… - … and clinical risk …, 2020 - Taylor & Francis
Patients with progressive chronic kidney disease (CKD) commonly develop mineral and
bone abnormalities and extraskeletal calcifications with following increased cardiovascular …
bone abnormalities and extraskeletal calcifications with following increased cardiovascular …
A review of phosphate binders in chronic kidney disease: incremental progress or just higher costs?
WLS Peter, LD Wazny, E Weinhandl, KE Cardone… - Drugs, 2017 - Springer
As kidney disease progresses, phosphorus retention also increases, and phosphate binders
are used to treat hyperphosphatemia. Clinicians prescribe phosphate binders thinking that …
are used to treat hyperphosphatemia. Clinicians prescribe phosphate binders thinking that …
Multidisciplinary perspectives of current approaches and clinical gaps in the management of hyperphosphatemia
M Vallée, J Weinstein, M Battistella… - … of Nephrology and …, 2021 - Taylor & Francis
Population-based studies have shown that most patients with advanced chronic kidney
disease (CKD) do not have optimal phosphate levels. Meta-analyses suggest that there is a …
disease (CKD) do not have optimal phosphate levels. Meta-analyses suggest that there is a …
The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia
AB Pai, JE Smeeding, RA Brook - Current medical research and …, 2004 - Taylor & Francis
Background: End-stage renal disease (ESRD) is a chronic health care problem associated
with multiple co-morbidities and escalating costs. Disregulation of mineral metabolism …
with multiple co-morbidities and escalating costs. Disregulation of mineral metabolism …
Treating hyperphosphatemia–current and advancing drugs
M Ketteler, O Liangos, PH Biggar - Expert Opinion on …, 2016 - Taylor & Francis
Introduction: Hyperphosphatemia is a hallmark of advanced chronic kidney disease (CKD)
and associated with adverse outcomes. Preclinical and epidemiological studies strongly …
and associated with adverse outcomes. Preclinical and epidemiological studies strongly …
Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients
SK Burke, MA Dillon, DE Hemken, MS Rezabek… - Advances in renal …, 2003 - Elsevier
Hyperphosphatemia and dyslipidemia are common clinically significant conditions in end-
stage renal disease (ESRD). Hyperphosphatemia management is essential; however, use of …
stage renal disease (ESRD). Hyperphosphatemia management is essential; however, use of …
相关搜索
- kidney disease meta analysis
- kidney disease phosphate binders
- impact of phosphate meta analysis
- kidney disease hyperphosphatemia patients
- hyperphosphatemia in patients meta analysis
- kidney disease sevelamer and lanthanum
- serum lipids meta analysis
- phosphate binders hyperphosphatemia patients
- sevelamer and lanthanum meta analysis
- hyperphosphatemia in patients clinical evaluation
- kidney disease mortality in people
- clinical evaluation renal disease
- kidney disease drugs in adults
- kidney disease efficacy and safety
- drugs in adults meta analysis
- efficacy and safety meta analysis